ArticlePloS one2026
Sarcopenia as an independent prognostic marker in liposarcoma: A longitudinal analysis of body composition and survival.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Resection of locally advanced soft tissue sarcomas of the extremities : Surgical strategies to avoid postoperative complications].Chirurgie (Heidelberg, Germany) · 2026Review
- Postoperative loss of skeletal muscle mass and visceral fat predicts survival and morbidity after surgically treated non-metastatic chondrosarcoma: a longitudinal CT morphometric study.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is increasingly recognized as an important prognostic factor in oncology; however, its clinical relevance in liposarcoma remains insufficiently defined. This study aimed to evaluate longitudinal changes in CT-derived body composition parameters in liposarcoma patients, to assess the influence of tumor grade, recurrence, and treatment modalities on these parameters and to determine the association of baseline sarcopenia and progressive muscle loss with overall survival and functional status.
methodsIn a retrospective, single center study between 2010 and 2024, 64 patients were analyzed. All patients underwent surgical tumor resection of a histologically confirmed liposarcoma. Included were patients with two consecutive CT scans. The following morphometric parameters were measured on CT axial images at the height of lumbar vertebral 3: Skeletal muscle index (SMI), paraspinal muscle index (PSMI), psoas muscle index (PMI), skeletal muscle density (SMD), and visceral adipose tissue (VAT). Standardized Hounsfield unit thresholds were used for the assessment. Additionally, the influence of tumor grade, recurrence, and treatment modalities on body composition was assessed. A Kaplan Meier survival analysis was performed using data from the residents´ registration office. Survival was further analyzed by Cox regression using uni- and multivariate models. Metric data was compared using student´s t-test.
resultsSignificant reductions in SMI, PSMI, PMI, and VAT were observed over the disease course, particularly among patients with high-grade tumors, chemotherapy, or local tumor recurrence. Baseline sarcopenia and a progressive SMI loss were independently associated with reduced overall survival. In multivariate analysis, baseline sarcopenia (HR: 2.331, p = 0.007) and a ≥ 15% SMI decline (HR: 2.601, p = 0.006) remained significant predictors of mortality. Both markers did not correlate with changes in Eastern Cooperative Oncology Group (ECOG) performance status.
conclusionCT-morphometric parameters deteriorate substantially during the disease course of liposarcoma patients and serve as independent predictors of survival. These findings support the integration of CT-based body composition analysis into routine oncologic assessment and highlight its potential role in identifying high-risk patients for early supportive intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.